(Updates with new CFO and sale of spinal implants businesses starting in the sixth paragraph)

Stryker (SYK) reported Q4 adjusted earnings late Tuesday of $4.01 per diluted share, up from $3.46 a year earlier.

Four analysts polled by FactSet expected $3.63.

Net sales in the three months ended Dec. 31 rose to $6.44 billion from $5.82 billion a year earlier. Analysts surveyed by FactSet expected $6.36 billion.

The company expects 2025 adjusted net earnings of $13.45 to $13.70 a share. Four analysts polled by FactSet expect $12.43.

The company expects full-year organic net sales growth of 8% to 9% versus the previous forecast of 9.5% to 10%. Analysts surveyed by FactSet expect revenue of $24.40 billion, if comparable.

Additionally, Stryker said it appointed Preston Wells as chief financial officer, starting April 1. Wells, who is currently Group CFO for Stryker's Orthopaedics Group, succeeds Glenn Boehnlein, who is retiring.

The company also said it agreed to sell its US spinal implants business to investment firm Viscogliosi Brothers, with the transaction expected to close in the first half of this year. Terms weren't disclosed.

Following the transaction, VB Spine, a newly formed company, will become a strategic partner to Stryker, with exclusive access to Mako Spine and Copilot technologies for use with VB Spine's implants in spine procedures.

Stryker's US spinal implants business and VB Spine will continue to operate as separate entities and proceed with business as usual until the transaction closes, according to the company.

The deal also includes a binding offer to acquire Stryker's spinal implants business in France.